
Keywords: Andro; Andrographolide; DR; diabetic retinopathy; STZ; streptozotocin; NPDR; non-proliferative DR; PDR; proliferative DR; CD31; cluster of differentiation 31; BRB; blood-retinal barrier; VEGF; vascular endothelial growth factor; ELISA; enzyme-linked immun